Dance Momsaired for nine seasons on Lifetime, and during that time, it produced a crop of memorable young dancers, like Lilliana Ketchman, aka Lilly K. Many of those young dancers, like Jojo Siwa and ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for weight management. Lilly said in an announcement that the model is built on ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

IT’S MORE THAN life-saving medicine. Lilly is a world premier medicine company, discovering innovative treatments to fight diseases like cancer, diabetes, and Alzheimer’s. Based in Indianapolis, Lilly ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies to provide direct access to their popular obesity meds. Thursday morning, ...

Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated ...

Early results showed that patients lost up to 20.1% of their body weight. Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 ...

Eli Lilly LLY-2.61%decrease; red down pointing triangle reported higher third-quarter profit and raised its full-year outlook on surging demand for its GLP-1 weight-loss drugs, sending its shares ...